Congressman Ditches Magnificent Seven Stocks for Consumer Staples: Here's What He Bought
A US congressman sold some Magnificent Seven stocks and replaced them with a couple consumer staples. Here's the trades.
Stocks · News reference
CHMP of the European Medicines Agency Recommends Approving Novo Nordisk's Once-Weekly Sogroya for Children with Idiopathic Short Stature with Persistent Growth Disturbance
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended once-weekly Sogroya® (somapacitan) for children in Europe living with idiopathic short stature (ISS) with
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Earlier: Sandoz Canada Launches Lower-Cost Generic Version Of Novo Nordisk’s Ozempic, Expanding Access to Semaglutide for Type 2 Diabetes
PrSandoz® Semaglutide, a generic version of PrOzempic®, approved for the treatment of adult patients with type 2 diabetesThis lower-cost alternative supports improved affordability and access to type 2 diabetes
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
Novo announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of denecimig (Mim8) for hemophilia A treatment in adults and children. The bispecific antibody offers flexible dosing options via subcutaneous prefilled pen and demonstrated low bleeding rates in FRONTIER clinical trials. Novo expects to launch the drug under the brand name Frehemgo in select European countries in Q4 2026, with broader EU rollout in early 2027. The drug is also under FDA review in the United States.